Inquiry Basket
CAS No.: 1313206-42-6
Cat No.: BADC-01606
4.5 
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. Polatuzumab vedotin has been approved for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL).
Structure of 1313206-42-6
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01614 | Glembatumumab vedotin | 1182215-65-1 | |
| BADC-01596 | Enfortumab vedotin-ejfv | 1346452-25-2 | |
| BADC-01610 | Tisotumab vedotin | 1418731-10-8 | |
| BADC-01597 | Ladiratuzumab vedotin | 1629760-29-7 | |
| BADC-01605 | Telisotuzumab vedotin | 1714088-51-3 | |
| BADC-01600 | Sirtratumab vedotin | 1824663-83-3 | |
| BADC-01604 | Disitamab vedotin | 2136633-23-1 | |
| BADC-00031 | Brentuximab vedotin | 914088-09-8 | |
| BADC-01613 | Zilovertamab vedotin |
Polatuzumab vedotin
Required fields are marked with *
Polatuzumab vedotin
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
